Trihexyphenidyl Use in a Parkinsonian Phenotype of Gerstman-Sträussler-Scheinker Syndrome
Objective: To highlight clinical improvement in a patient with a parkinsonian presentation of Gerstmann-Sträussler-Scheinker (GSS) syndrome who was treated with trihexyphenidyl. Background: GSS is a…Potentially inappropriate medication useage among patients newly diagnosed with dementia with Lewy bodies
Objective: Investigate the use of potentially inappropriate medications (PIM) among patients newly diagnosed with dementia with Lewy bodies (DLB). Background: PIM, including anticholinergics, are associated…Association Between Anticholinergic Burden, MCI, and Cholinergic Denervation
Objective: To characterize the relationship between anticholinergic burden (ACB), mild cognitive impairment (MCI), and its underlying cholinergic pathology. Background: MCI is a common phenomenon in…Hyperkinetic movement disorder following Covid: A Temporal corelation or Coincidental ?
Objective: Hypokinetic movement disorder and parkinsonian like picture has been well described in literature but hyperkinetic movements are extremely rare and less highlighted in global…Adult-onset axial dystonia: a rare condition that can lean on an early combined treatment approach
Objective: To describe a rare case of adult-onset axial dystonia treated successfully with a combined therapeutic approach. Background: Adult-onset truncal dystonia is an unusual condition…Changes in anticholinergic burden in patients with Parkinson’s disease (PD) after bilateral deep brain stimulation (DBS) of the globus pallidus (GP) and subthalamic nucleus (STN)
Objective: To evaluate the effect of GP and STN DBS upon anticholinergic medication burden in patients with PD. Background: Medications with anticholinergic effects are commonly…Low dose trihexyphenidyl use causes cognitive dysfunction in Parkinson’s disease patients.
Objective: Evaluate cognitive performance in Parkinson's disease patients receiving a low dose of trihexyphenidyl (THP). Background: Before L-Dopa's discovery, anticholinergic drugs were among the first…Anticholinergic Use in Parkinson’s Disease: Practice Patterns in Patients with Cognitive Impairment
Objective: To explore utilization of anticholinergic medications using the Parkinson Foundation Quality Improvement Initiative (PF-QII) registry. Background: Recent publications have highlighted the association between anticholinergic…Effectiveness and Tolerability of Mirabegron and Behavioral Therapy in Patients with Parkinson’s Disease and Overactive Bladder: A Prospective, Randomized, Placebo-Controlled Pilot Study
Objective: To assess safety, tolerability, and efficacy of mirabegron and Pelvic floor Exercise (PFE)-based behavioral therapy for the treatment of overactive bladder (OAB) in patients…Anticholinergic Burden in Parkinson’s Disease Patients in India – A Hospital Based Study
Objective: To determine the cumulative anticholinergic burden in Indian Parkinson’s disease (PD) patients and to correlate the same with cognitive impairment and gait disturbance. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.